COLL

Business Context and Reporting Period

Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Collegium is a biopharmaceutical company commercializing products for ADHD (Jornay PM) and pain management (Belbuca, Xtampza ER, Nucynta Products, Symproic). The company recently announced the acquisition of AZSTARYS® to expand its neuropsychiatry portfolio.

Key Financial Metrics

Note: Cash & Marketable Securities calculated as Cash ($268,648) + Marketable Securities ($153,105). Total Debt includes Term Notes ($564,348 carrying value) and Convertible Senior Notes ($238,472 carrying value).

Material Changes vs. Prior Period

• Revenue Growth: Net product revenues increased by $15.7 million (8.8%) year-over-year. Growth was driven by Jornay PM (+$10.4M), Xtampza ER (+$3.1M), Symproic (+$1.4M), and Belbuca (+$1.0M). This was partially offset by a slight decrease in Nucynta branded revenue due to the launch of authorized generics in Q1 2026.
• Profitability: Net income surged to $14.5 million from $2.4 million, primarily due to higher operating income ($30.9M vs $21.7M) and reduced interest expense ($15.9M vs $20.8M) following debt refinancing.
• Operating Expenses: SG&A expenses increased by $10.0 million to $86.4 million. This increase was largely attributed to $4.9 million in acquisition-related expenses for the pending AZSTARYS® deal, higher sales force costs for Jornay PM, and increased salaries.
• Debt Structure: The company refinanced its 2024 Term Loan in December 2025 with a new 2025 Credit Facility, resulting in lower interest rates and a reduced principal balance compared to the prior year.

Guidance, Outlook, and Risks

• AZSTARYS® Acquisition: On March 19, 2026, Collegium agreed to acquire AZSTARYS® for $650 million in cash, with potential milestones up to $135 million. The deal is expected to close in Q2 2026, funded by existing cash and a delayed draw term loan.
• Generic Competition: Authorized generic versions of Nucynta IR and ER launched in February and March 2026, respectively. While this impacted branded revenue, it generated new authorized generic revenue streams.
• Liquidity: Management believes current cash, cash equivalents, and marketable securities ($421.8 million) combined with operating cash flows are sufficient to fund operations and debt service for the foreseeable future.
• Key Risks:
  • Regulatory & Litigation: Ongoing patent litigation with Purdue (Xtampza ER, Nucynta) and generic competitors (Alvogen, Chemo Research). Potential for unfavorable outcomes in opioid-related investigations.
  • Supply Chain: Reliance on third-party manufacturers and limited suppliers for active pharmaceutical ingredients (APIs), particularly for controlled substances like methylphenidate (Jornay PM).
  • Integration: Risks associated with integrating the AZSTARYS® acquisition and realizing anticipated synergies.

Investor Verification Checklist

• AZSTARYS® Closing Conditions: Verify the status of regulatory approvals and closing conditions for the $650 million acquisition expected in Q2 2026.
• Nucynta Revenue Mix: Monitor the impact of the authorized generic launch on total Nucynta franchise revenue and gross margins in subsequent quarters.
• Debt Covenants: Review compliance with the 2025 Credit Facility covenants, specifically the First Lien Net Leverage Ratio and Fixed Charge Coverage Ratio.
• Patent Litigation Status: Track developments in the Purdue litigation regarding Xtampza ER and Nucynta, as well as the Alvogen and Chemo Research cases regarding Belbuca.
• Supply Chain Stability: Assess any potential disruptions in the supply of methylphenidate for Jornay PM given recent DEA quota adjustments and market shortages.